Zhenguo Zhai
Zhenguo Zhai publishes mostly in Pulmonary and Respiratory Medicine, Internal Medicine and Cardiology and Cardiovascular Medicine, on topics such as Venous Thromboembolism Diagnosis and Management, Pulmonary Hypertension Research and Treatments and Atrial Fibrillation Management and Outcomes.
- World rank
- #1,124,632 of 7,710,434 ranked researchers
- Rank in China
- #161,073 of 978,568
- Works
- 255
- Citations
- 3.9k
- Citations per work
- 15.3
What does Zhenguo Zhai research?
Zhenguo Zhai's work is mostly in Medicine (66%), Biochemistry, Genetics and Molecular Biology (4%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences16966.1%
- Medicine16966.1%
- Everything else7830.4%
- Life Sciences93.5%
- 1Pulmonary and Respiratory Medicine23% of their works
- 2Internal Medicine17% of their works
- 3Cardiology and Cardiovascular Medicine15% of their works
- 4Surgery6% of their works
- 5Hematology5% of their works
- 6Molecular Biology4% of their works
Research topics
- Venous Thromboembolism Diagnosis and Management
- Pulmonary Hypertension Research and Treatments
- Atrial Fibrillation Management and Outcomes
- Blood Coagulation and Thrombosis Mechanisms
- COVID-19 Clinical Research Studies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cardiovascular Function and Risk Factors
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Which keywords describe Zhenguo Zhai's research?
The keywords of their largest research topics: Antithrombotic Therapy, Diagnosis, Pulmonary Embolism, Venous Thromboembolism, Echocardiography, Pulmonary Hypertension, Right Heart Assessment and Anticoagulant Therapy.
- Fibrosis
- Chamber Quantification
- Heparin-Induced Thrombocytopenia
- Clinical Characteristics
- Protease-Activated Receptors
- Immune Response
- Anticoagulant Therapy
- Pulmonary Hypertension
- Venous Thromboembolism
- Diagnosis
- Antithrombotic Therapy
- Pulmonary Embolism
- Echocardiography
- Right Heart Assessment
- Atrial Fibrillation
- Thrombosis
- Thrombin
- SARS-CoV-2
- Vaccination
- Diastolic Function
- Idiopathic Pulmonary Fibrosis
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 21 words, with their numbers
- Antithrombotic Therapy1472 topics
- Diagnosis1312 topics
- Pulmonary Embolism1171 topic
- Venous Thromboembolism1171 topic
- Echocardiography1132 topics
- Pulmonary Hypertension1011 topic
- Right Heart Assessment1011 topic
- Anticoagulant Therapy391 topic
- Atrial Fibrillation391 topic
- Immune Response322 topics
- Thrombosis322 topics
- Protease-Activated Receptors301 topic
- Thrombin301 topic
- Clinical Characteristics181 topic
- SARS-CoV-2181 topic
- Heparin-Induced Thrombocytopenia141 topic
- Vaccination141 topic
- Chamber Quantification121 topic
- Diastolic Function121 topic
- Fibrosis121 topic
- Idiopathic Pulmonary Fibrosis121 topic
Where does Zhenguo Zhai work?
Zhenguo Zhai's main affiliation in the publication record is China-Japan Friendship Hospital, China.
How many publications and citations does Zhenguo Zhai have?
OpenAlex counts 255 works and 3,889 citations for Zhenguo Zhai, an h-index of 30, ranking #1,124,632 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Other researchers named Zhenguo Zhai
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Zhenguo Zhai. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.